Sulfamethoxazole is a sulfonamide antibiotic that inhibits bacterial folate synthesis by competitively blocking the enzyme dihydropteroate synthase, which is crucial for the production of nucleic acids. It is clinically significant for treating a variety of bacterial infections, particularly urinary tract infections and respiratory infections, often in combination with trimethoprim to enhance efficacy. A key association is its use in treating Pneumocystis jirovecii pneumonia in immunocompromised patients, highlighting its importance in managing opportunistic infections.